Ignite Creation Date:
2024-05-06 @ 8:16 PM
Last Modification Date:
2024-10-26 @ 3:24 PM
Study NCT ID:
NCT06314373
Status:
RECRUITING
Last Update Posted:
2024-03-18
First Post:
2024-02-29
Brief Title:
A Study for HSK39775 in Participants With Solid Tumors
Sponsor:
Xizang Haisco Pharmaceutical Co Ltd
Organization:
Haisco Pharmaceutical Group Co Ltd
Study Overview
Official Title:
A Phase III Study to Assess the Safety Tolerability PKPD and Preliminary Efficacy of HSK39775 Tablet Monotherapy in Participants With Advanced Solid Malignancies
Status:
RECRUITING
Status Verified Date:
2024-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This research is designed to determine if HSK39775 is safe tolerable and has anti-cancer activity in patients with advanced solid tumors
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None